Here’s a roundup of recent clinical trial news:
- JenaValve reports significant clinical milestone: first-ever successful transcatheter implantation of a 27mm transapical aortic valve prosthesis
JenaValve™ Technology Inc., a medical device company specializing in developing transcatheter aortic valve implantation (TAVI) systems, announced a significant clinical milestone: the first-ever successful transcatheter implantation of a 27mm transapical aortic valve prosthesis.
Read more - Combination of home blood pressure monitoring & doctor visits keeps the numbers you need to know in check
A recent research review has concluded that home blood pressure monitors can help people keep their blood pressure in check and possibly cut down on medication – as long as patients and their doctors put those home readings to good use(1). For years, Omron Healthcare Inc. has reminded Americans how important home blood pressure monitoring is when it comes to reducing their risk of a heart attack or stroke, and truly wants people to take the news to heart in 2011.
Read more - Study on HIV/AIDS redefines the size, scale and scope of epidemic
Health Alert Communications, www.healthalert.net, announces the publication of its groundbreaking report, HIV/AIDS: The Jennings Report – Redefining the Size, Scope, and Scale of the AIDS Epidemic by Forensic Review of the Medical Literature, available from MarketResearch.com and ResearchAndMarkets.com, the world’s distributors of market intelligence.
Read more - Johns Hopkins study shows Masimo noninvasive hemoglobin monitoring is accurate during complex spine surgeries
Masimo (NSDQ:MASI) announced that a new clinical study demonstrating the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented last week at the Society for Technology in Anesthesia (STA) Annual Meeting.
Read more - NIH-funded study is first to demonstrate increased long-term survival with favorable neurologic function among patients receiving CPR using ASCI Resqpump and Resqpod CPR devices
A combination of two devices could save the lives of thousands of cardiac arrest patients each year if implemented nationwide, suggests clinical trial results published in today’s online edition of The Lancet. A significantly higher percentage of patients who experienced out-of-hospital cardiac arrest survived after receiving active compression decompression cardiopulmonary resuscitation (ACD CPR) performed with the ResQPump®, and the ResQPOD® impedance threshold device, as compared to those receiving conventional, manual CPR performed with a pair of hands. Both devices are manufactured by Advanced Circulatory Systems Inc. (ACSI) in Roseville, Minn.
Read more - Internet-based rehab is a viable treatment option following knee surgery
Knee replacement patients undergoing telerehabilitation – a unique Internet-based postoperative rehabilitation program that can be conducted from the patient’s home – experience the same results as patients who undergo traditional postoperative rehabilitation, according to a new study published in the Journal of Bone and Joint Surgery (JBJS). Telerehabilitation is becoming a popular alternative for patients who live in remote areas and who have no access to traditional rehabilitation centers.
Read more - NIH study in mice uncovers pathway critical for UV-induced melanoma
Scientists have made an unanticipated discovery in mice that interferon-gamma, a type of protein primarily used by the immune system for intercellular communication, acts as a promoter for the deadly form of skin cancer known as melanoma. This finding resulted from a series of experiments designed to understand how solar ultraviolet (UV) radiation causes melanoma. The results of this study suggest that interferon-gamma, which has been thought to contribute to an innate defense system against cancer, under some circumstances may promote melanoma and incite the development of tumors. The work, led by researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, appeared online in Nature, Jan. 19, 2011.
Read more - PROSPECT study published in The New England Journal of Medicine demonstrates that volcano’s IVUS and VH IVUS technologies can assess risk of a future clinical event better than using angiography alone
Volcano Corporation (NSDQ:VOLC) announced the publication of results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study in The New England Journal of Medicine showing that grayscale intravascular ultrasound (IVUS) and Volcano’s proprietary VH® IVUS tissue characterization software enable physicians to more accurately assess the risk of individual blockages than the use of the current standard-of-care– angiographic imaging– alone.
Read more - Clinical study finds Masimo noninvasive hemoglobin accurate in patients with critically low hemoglobin levels
Masimo (NSDQ:MASI) announced that a new study demonstrating the clinical accuracy and value of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented this week at the Society of Critical Care Medicine (SCCM) Annual Critical Care Congress in San Diego. The largest multi-professional critical care event of the year, the SCCM Annual Congress reflects the latest in evidence-based research, clinical best practices, and medical developments that are shaping the future of critical care medicine.
Read more - BSD Medical reports publication of German oncology journal Der Onkologe emphasizing benefits of hyperthermia in treatment of cancer
BSD Medical Corporation (NSDQ:BSDM) announced publication of an issue of the official journal of the German Cancer Society, Der Onkologe, that is dedicated to the current role of hyperthermia in cancer treatment. The publication focuses on all aspects of the role of hyperthermia in clinical oncology and emphasizes the benefits of hyperthermia for the treatment of recurrent breast cancer, advanced rectal and cervical cancer, and anal cancer.
Read more - NEJM: Prospective natural-history study of coronary atherosclerosis funded by Abbott and Volcano
In patients who presented with an acute coronary syndrome and underwent percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up were equally attributable to recurrence at the site of culprit lesions and to nonculprit lesions. Although nonculprit lesions that were responsible for unanticipated events were frequently angiographically mild, most were thin-cap fibroatheromas or were characterized by a large plaque burden, a small luminal area, or some combination of these characteristics, as determined by gray-scale and radiofrequency intravascular ultrasonography.
Read more - Nfocus Neuromedical Luna aneurysm embolization system demonstrates clinical utility in brain aneurysm
Nfocus Neuromedical Inc., an innovative medical device company with a focus on the next generation treatment for brain aneurysms, announced the presentation of preliminary clinical experience for the company’s Luna™ Aneurysm Embolization System (AES). Drs. Gyula Gal and Karlis Kupc of the Departments of Radiology University Hospitals in Odense, Denmark and Riga, Latvia presented results from their first use of the Luna AES at the annual ABC-WIN meeting here.
Read more - Everist Genomics announces external validation of oncodefender-CRC test for predicting recurrence risk for stage I and II colorectal cancer patients
Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with investigators and resources from all three Mayo Clinic sites. The study, which will be presented in a poster presentation on Saturday at the American Society of Clinical Oncology’s 2011 Gastrointestinal Cancers Symposium (ASCO-GI) in San Francisco, demonstrates that the OncoDefender-CRC assay can accurately predict individual recurrence risk in stage I and II colorectal cancer patients.
Read more
